BackFresenius Medical Care AG Overview
Fresenius Medical Care AG - ADR

Fresenius Medical Care AG Target Price

Where could FMS trade next? Consensus target price: $24.

Get informed when a big investor buys or sells

+ Follow

Share Price

$22.68

Average Target Price

$23.684.4% upside

4 analysts in the last 4 months

High: $25.8 | Low: $19.9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-29Berenberg BankHarry Gillis$245.8% upsideOpen
2026-08-06BernsteinSusannah Ludwig$25.813.8% upsideOpen
2026-08-05Truist Financial$2510.2% upsideOpen
2026-07-28BNP Paribas$19.912.3% downsideOpen
2026-01-05Truist Financial$2823.5% upsideOpen
2024-05-15Truist FinancialDavid MacDonald$245.8% upsideOpen
2023-01-02JefferiesJames Vane-Tempest$11.748.4% downsideOpen
2022-06-22Truist Financial$2719% upsideOpen

Fresenius Medical Care AG (FMS) FAQ

Fresenius Medical Care AG (FMS) currently reports a target price of $24. Use the charts on this page to explore Fresenius Medical Care AG's target price history and peer comparisons.

Analysts' average 12-month price target for Fresenius Medical Care AG is $24, about 4.4% upside from the current share price of $22.68. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $24, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fresenius Medical Care AG, and consider following FMS for alerts when major investors trade the stock.

Fresenius Medical Care AG is classified in the Healthcare sector. On target price, it currently shows $24. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FMS with unrelated industries.